Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06570798
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-22
Brief Title:
A Phase 2a Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 2a Open Label Multi Center Platform Trial to Assess the Safety Tolerability and Efficacy of Inebilizumab and Blinatumomab in Subjects With Autoimmune Diseases
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main objective is to assess the safety and tolerability of inebilizumab Subprotocol A and subcutaneous SC blinatumomab Subprotocol B in adult participants with active and refractory systemic lupus erythematosus SLE with nephritis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None